Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Slideshows|August 24, 2017

Psychiatric Times CMEs: Mid-Year Review

Author(s)Laurie Martin

Here is a rundown of 6 soon-to-expire free CME activities you can take right now.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

5 Medical Comorbidities Linked to Depression in Older Patients

ByFred Liu, MD,Awais Aftab, MD

March 30th 2021

10 Facts About Geriatric Pharmacotherapy

BySandra Jacobson, MD

March 15th 2021

3 Important Facts About Domestic Violence

ByLaurie Martin

February 21st 2020

5 Manifestations of Methamphetamine Poisoning

ByAnna Moszczynska, PhD

February 11th 2020

6 Myths About Integrative Psychiatry

ByScott Shannon, MD

October 11th 2018

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Trending on Psychiatric Times

FDA Clears First and Only Single-Biomarker Blood Test for Alzheimer Disease Assessment

Patent Application Published: MDMA-N-Acylethanolamines for the Treatment of PTSD, Anxiety, and Eating Disorders

Kratom Component in Clinical Trial for Opioid Use Disorder

Migraine and Psychiatric Comorbidities

NIDA Awards PleoPharma $6.5 Million Grant to Advance Phase 3 Trial of PP-01 for Cannabis Use Disorder